brian lehmann

Research Assistant Professor

Vanderbilt University Medical Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (34)

Purpose: Immune checkpoint inhibitors (ICI) have increasing application in endometrial cancer, underscoring the need for robust biomarkers for patient selection. JAK1 pathogenic variants (PV) have previously been implicated in immune evasion. In this study, we identify biomarkers predictive of ICI response in endometrial cancer and the implications of JAK1 PVs in this context. Experimental Design: This is a translational study of tumors from 84 patients with endometrial cancer treated with ICIs. High-throughput proteomic-based profiling was used to quantify 193 phosphoprotein/protein expression levels, including key JAK/STAT signaling pathway components. Associations with clinical outcomes were assessed using multivariate regression analysis. The functional consequences of JAK1 PVs were explored through in vitro signaling assays and analyses of The Cancer Genome Atlas database. Results: MHC-I expression correlated with improved progression-free survival ( P = 0.035), validated in orthogonal approaches. Notably, a subset of patients harboring JAK1 PVs demonstrated exceptional survival on ICIs. In The Cancer Genome Atlas cohort of microsatellite instability–high and DNA polymerase epsilon–mutated tumors, homozygous loss of JAK1 trended toward decreased survival, whereas heterozygous loss of JAK1 was associated with significantly improved survival ( P = 0.026), suggesting partial retention of antigen presentation pathways. Among our ICI-treated microsatellite instability–high tumor samples, NK cell marker NCAM1 was associated with improved survival ( P = 0.02). Conclusions: These data support MHC-I as a potential predictive biomarker for ICI response in endometrial cancer. Additionally, we show that partial retention of JAK1 signaling in JAK1 tumors with heterozygous loss is associated with improved survival, potentially attributable to enhanced NK cell activity in tumors with low MHC-I expression.

Year:

2025

Purpose: We report herein a phase Ib trial to determine the safety, tolerability, and antitumor activity of erdafitinib, a pan-FGFR tyrosine kinase inhibitor, with fulvestrant and palbociclib in patients with hormone receptor–positive/HER2-negative metastatic breast cancers (NCT03238196). Patients and Methods: Thirteen patients were enrolled on the escalation phase in a traditional 3 + 3 trial design to determine the maximum tolerated dose (MTD). Subsequently, 22 patients were treated at the established MTD during the expansion phase. All patients had received prior treatment with cyclin-dependent kinase-4/6 inhibitors and endocrine therapy, and 29 showed FGFR pathway alterations in their tumors. Results: The MTD of erdafitinib was 6 mg taken orally once daily when combined with palbociclib and fulvestrant. The triple combination showed clinically manageable tolerability. Most common adverse events were neutropenia, likely attributable to palbociclib, and oral mucositis and hyperphosphatemia, attributable to erdafitinib. Three patients showed a partial response, one of them lasting more than 2.5 years, despite lacking detectable FGFR1 to FGFR4 somatic alterations. FGFR1 amplification was not associated with response to FGFR inhibition, but high FGFR1 protein expression, measured by IHC, correlated with longer progression-free survival within the FGFR1-amplified cohort. There was no correlation between FGFR1 copy number and FGFR1 protein levels in specimens from metastatic sites, potentially highlighting the need for a more recent metastatic tumor biopsy for biomarker evaluation. Conclusions: The trial endpoint was met establishing the MTD of erdafitinib at 6 mg. Whereas the triplet regimen may pose tolerability challenges, alterative doublets with selective FGFR1 inhibitors in patients with FGFR1-dependent tumors, possibly administered in sequence, are worthy of further investigation.

Year:

2025

Obesity is an established risk factor for breast cancer development and poor prognosis. The adipose environment surrounding breast tumors, which is inflamed in obesity, has been implicated in tumor progression, and triggering receptor expressed on myeloid cells 2 (TREM2), a transmembrane receptor expressed on macrophages in adipose tissue and tumors, is an emerging therapeutic target for cancer. A better understanding of the mechanisms for the obesity–breast cancer association and the potential benefits of weight loss could help inform treatment strategies. In this study, we utilized lean, obese, and weight-loss mouse models to examine the impact of TREM2 deficiency on postmenopausal breast cancer depending on weight history conditions. Trem2 deficiency constrained tumor growth in lean, but not in obese or weight-loss, mice. Single-cell RNA sequencing, in conjunction with variable–diversity–joining sequencing, of tumor and tumor-adjacent mammary adipose tissue immune cells revealed differences in the immune landscapes across the different models. Tumors of lean TREM2-deficient mice exhibited a shift in clonal CD8 + T cells from an exhausted to an effector memory state, accompanied by increased clonality of CD4 + Th1 cells, that was not observed in any other diet-genotype group. Notably, identical T-cell clonotypes were identified in the tumor and tumor-adjacent mammary adipose tissue of the same mouse. Finally, anti–PD-1 therapy restricted tumor growth in lean and weight-loss, but not in obese, mice. These findings indicate that weight history could affect the efficacy of TREM2 inhibition in postmenopausal breast cancer. The reported immunologic interactions between tumors and the surrounding adipose tissue highlight significant differences under obese and weight-loss conditions. Significance: Weight history impacts the immunological landscape of postmenopausal breast cancer and the efficacy of TREM2 modulation and anti–PD-1 therapy, which has implications for personalized medicine.

Year:

2025

Supplemental Figure 7. B7-H4 and PD-L1 are not mutually exclusive on tumor cells. Data shown are reverse phase protein array expression data of B7-H4 and PD-L1 (SP142, 22C3, or Atezolizumab) from the I-SPY2 patient cohort. Samples were a mixture of TNBC and ER+ tumors and were treated with chemotherapy ± anti-PD-1. Depending on the antibody clone selected to detect PD-L1 expression, B7-H4 had no correlation, or a positive correlation to PD-L1 expression in these tumors. Data analyzed by spearman correlation and shown with linear regression best-fit line. n = 151 patients.

Year:

2024

Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antibody. Differentially expressed genes are shown. n = 6 mice per group. (B) Macrophage function was upregulated in B7-H4+ tumors, but minimal other differences were seen. (C) Differentially expressed genes between control and B7-H4+ tumors at a later stage. n = 12 mice per group. CD45+ cells were harvested when tumors reached 500mm3. (D) Macrophage function remains elevated in B7-H4+ tumors, but minimal differences were detected. Data were analyzed by Wilcoxon rank sum test. Genes with log2 fold change >0.5 or

Year:

2024

Supplemental Figure 5. CD45+ gene expression changes from early and later tumor stage between EMT6 control and B7-H4+ tumors. (A) CD45+ cells were isolated from EMT6 control or B7-H4+ tumors 7 days post treatment with isotype control antibody. Differentially expressed genes are shown. n = 6 mice per group. (B) Macrophage function was upregulated in B7-H4+ tumors, but minimal other differences were seen. (C) Differentially expressed genes between control and B7-H4+ tumors at a later stage. n = 12 mice per group. CD45+ cells were harvested when tumors reached 500mm3. (D) Macrophage function remains elevated in B7-H4+ tumors, but minimal differences were detected. Data were analyzed by Wilcoxon rank sum test. Genes with log2 fold change >0.5 or

Year:

2024

Supplemental Figure 4. B7-H4 expression did not change quantity of infiltrating tumor immune cells in vivo regardless of anti-PD-L1 treatment. Untreated and anti-PD-L1 treated EMT6 tumors ± B7-H4 were dissociated to single cell suspension and subjected to flow cytometry with a 14 (for myeloid cells) or 17 (for T cells) color panel on a CyTEK Aurora. n = 3/group for control and 8/group for treated samples. Data were analyzed by One-way ANOVA with Sidak’s post-hoc test for multiple comparisons between the EMT6 control anti-PD-L1 and EMT6 B7-H4+ anti-PD-L1 treatment groups. One-way ANOVA was not significant between groups. Data were analyzed in GraphPad Prism v10.

Year:

2024

Supplemental Figure 3. B7-H4 was expressed on some tissue immune cells in the C57BL/6 model, but not the BALB/c model. (A) Formalin-fixed, paraffin-embedded sections of BALB/c and C57BL/6 mice were stained for B7-H4, CD45, and DAPI using multiplexed immunofluorescence, or B7-H4 by IHC. CD45+ B7-H4+ cells were observed in spleen and intestine in C57BL/6 mice but not BALB/c mice. (B) Based on morphological characterization, these are likely macrophages. BALB/c spleen, intestine, and other healthy tissues examined (lymph node, fat pad, lung) had no B7-H4+ immune cells. Scale bar 20µm. (C) Flow cytometry of B7-H4+ cells are not present in the BALB/c spleen but are in the C57BL/6 spleen, similar to our findings by mIF. (D) Representation of flow cytometry scatter plots. B7-H4+ immune cells were only found in the C57BL/6 spleen, not bone marrow (b.m.)

Year:

2024

B7-H4 expression is regulated by PI3K signaling. A, Spearman correlations in protein expression from RPPA data collected from patients from the ISPY2 trial. Key positive correlations are called out in blue and key negative correlations are called out in red. B, RPPA data show strong positive correlations between B7-H4 and AKT (pAKT-Ser 473) and strong negative correlations between B7-H4 and PTEN (Ser 380) regardless of tumor hormone receptor status. C, PI3K inhibitor (buparlisib) treatment for 72 hours robustly decreases B7-H4 expression in human MDA-MB-468 breast cancer cells, while MEK inhibitor (trametinib) has no effect. D, Likewise, in MMTV-neu cells, buparlisib reduces B7-H4 expression in dose-dependent manner after 72 hours. Data were analyzed by one-way ANOVA with Dunnet post hoc test for multiple comparisons, P P = 0.0005).

Year:

2024

B7-H4 is associated with immune cold tumors and correlated with worse outcomes. A, Representative TNBC samples (residual disease, post-NAC) categorized on the basis of CD8 T-cell infiltration and localization into ID, MR, SR, and FI. B, B7-H4 is heterogeneously expressed in TNBC. C, ID and MR tumors have the highest level of B7-H4 expression ( n = 69: ID: 19, MR: 17, SR: 14, FI: 19). MR and SR tumors were analyzed by unpaired t test. D, MR and ID tumors also have worse RFS and OS ( n = 69). Data were analyzed by Mantel–Cox test. E, B7-H4 expression directly correlates with worse outcomes in patients ( n = 77; >60%: 16, F, TNBC samples stained with immunofluorescent markers for DAPI, panCK, CD3, and CD8 to identify regions of interest (ROI) for NanoString GeoMX DSP. MR and SR panCK+ ROIs were selected and differential protein expression between tumor samples is shown. G, Within the panCK gated cells, MR tumors had higher EpCAM expression. SR tumors had higher CD44 expression, as well as higher PD-L1. Data shown are log 2 fold change of differentially expressed genes ( P q

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (30)

Yu Wang

Staff Scientist

Vanderbilt University Medical Center

UNITED STATES
View details

Vijaya Bharti

Research assistant professor

Vanderbilt University

UNITED STATES
View details

Erica Carballo

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Justin M. Balko

Vanderbilt University Medical Center

UNITED STATES
View details

Barbara Fingleton

Associate Professor

Vanderbilt University

UNITED STATES
View details

Payal D. Shah

University of Pennsylvania

UNITED STATES
View details

Kathryn E. Wellen

University of Pennsylvania

UNITED STATES
View details

Xiaopeng Sun

Vanderbilt University

UNITED STATES
View details

Erica M. Stringer-Reasor

Associate Professor

The University of Alabama

UNITED STATES
View details

Tarah Ballinger

Associate Professor of Medicine

Indiana University School of Medicine

UNITED STATES
View details

Ben Ho Park

Vanderbilt University Medical Center

UNITED STATES
View details

Liza Makowski

Professor

University of Tennessee Health Science Center

UNITED STATES
View details

Gillian Hirst

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Rosa Isela Gallagher

Senior Research Scientist

George Mason University

UNITED STATES
View details

Luc Van Kaer

Vanderbilt University School of Medicine

UNITED STATES
View details

QI LIU

Vanderbilt University Medical Center

UNITED STATES
View details

Cesar Santa-Maria

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Andres Ocampo

Vanderbilt University

UNITED STATES
View details

Juliana Bronzini

Vanderbilt University

UNITED STATES
View details

Carlos L. Arteaga

University of Texas Southwestern Medical Center

UNITED STATES
View details

Alyssa H. Hasty

Vice Provost

Vanderbilt University

UNITED STATES
View details

Laura Esserman

University of California

UNITED STATES
View details

Claudine Isaacs

Professor of Medicine

Georgetown University

UNITED STATES
View details

Laura J. van 't Veer

University of California, San Francisco

UNITED STATES
View details

LAMORNA SWIGART

University of California, San Francisco

UNITED STATES
View details

John T. Wilson

Vanderbilt University

UNITED STATES
View details

Vandana Abramson

Professor of Medicine

-

UNITED STATES
View details

BJ Rimel

Division Chief, Gynecologic Oncology

Fred Hutch Cancer Center

UNITED STATES
View details

Courtney Penn

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Jeffrey C. Rathmell

Chair and Professor

University of Chicago

UNITED STATES
View details